Modality
ADC
MOA
Anti-Tau
Target
PARP
Pathway
Tau
PompeET
Development Pipeline
Preclinical
~Aug 2012
→ ~Nov 2013
Phase 1
~Feb 2014
→ ~May 2015
Phase 2
~Aug 2015
→ ~Nov 2016
Phase 3
Feb 2017
→ Nov 2031
Phase 3Current
NCT03243895
810 pts·Pompe
2017-02→2029-12·Terminated
NCT05341929
2,587 pts·Pompe
2021-06→2031-11·Terminated
3,397 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2029-12-073.7y awayPh3 Readout· Pompe
2031-11-015.6y awayPh3 Readout· Pompe
Trial Timeline
2017Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P3
Termina…
P3
Termina…
Catalysts
Ph3 Readout
2029-12-07 · 3.7y away
Pompe
Ph3 Readout
2031-11-01 · 5.6y away
Pompe
Terminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03243895 | Phase 3 | Pompe | Terminated | 810 | SRI-4 |
| NCT05341929 | Phase 3 | Pompe | Terminated | 2587 | PASI75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Miriosocimab | Pfizer | Phase 1 | PARP | |
| RHH-7558 | Roche | Phase 1 | SGLT2 | |
| NVS-5439 | Novartis | Preclinical | BET | |
| NVO-9630 | Novo Nordisk | Phase 2 | CD3 | |
| NVO-2974 | Novo Nordisk | NDA/BLA | PARP | |
| Semainavolisib | Gilead Sciences | Phase 2 | PARP | |
| REG-861 | Regeneron | Phase 2 | PARP | |
| REG-2172 | Regeneron | Phase 1/2 | PCSK9 | |
| BGN-3305 | BeiGene | Phase 2 | BCMA | |
| Sovarasimod | Halozyme | Phase 1/2 | WEE1 |